Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct:177:113911.
doi: 10.1016/j.addr.2021.113911. Epub 2021 Aug 3.

Therapeutic and delivery strategies of phytoconstituents for renal fibrosis

Affiliations
Review

Therapeutic and delivery strategies of phytoconstituents for renal fibrosis

Huan Xu et al. Adv Drug Deliv Rev. 2021 Oct.

Abstract

Chronic kidney disease (CKD) is one of the most common diseases endangering human health and life. By 2030, 14 per 100,000 people may die from CKD. Renal fibrosis (RF) is an important intermediate link and the final pathological change during CKD progression to the terminal stage. Therefore, identifying safe and effective treatment methods for RF has become an important goal. In 2018, the World Health Organization introduced traditional Chinese medicine into its effective global medical program. Various phytoconstituents that affect the RF process have been extracted from different plants. Here, we review the potential therapeutic capabilities of active phytoconstituents in RF treatment and discuss how phytoconstituents can be structurally modified or combined with other ingredients to enhance efficiency and reduce toxicity. We also summarize phytoconstituent delivery strategies to overcome renal barriers and improve bioavailability and targeting.

Keywords: Combined administration; Delivery strategies; Phytoconstituents; Renal fibrosis; Structural modification.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: L.H. is a consultant for Samyang Biopharmaceuticals, PDS Biotechnology and Stemirna. The rest of the authors report no conflict of interest in this work..

Publication types

LinkOut - more resources